



**Use of Microscopic-observation Drug
Susceptibility Assay (MODS) among Drug-
Resistant Tuberculosis Suspects in Harare,
Zimbabwe**

by
Beauty Makamure



Structure

- Introduction
 - Study Question
 - Objectives
 - Study Methodology
 - Results
 - Conclusion
- 

Introduction


- ▶ The WHO estimates a global prevalence of 650,000 cases of MDR-TB, contributing to 150,000 annual deaths.(1)
- ▶ Despite these staggering figures, only 6% of worldwide cases are detected.(2)
- ▶ DST for surveillance and patient management in high burden countries is urgently needed

1 WHO global report 2010


2 Who. Global TB control – epidemiology, strategy, financing. 2009

Introduction


- ▶ MODS assay :
 - liquid culture-based diagnostic test based on characteristic cording of *Mtb*.
 - Accurate and inexpensive test.
 - Endorsed by the WHO for rapid screening of patients suspected of having MDR-TB.
- ▶ Despite calls for an expanded role for use of the MODS assay in high HIV-prevalence regions, data among HIV-infected TB and MDR-TB suspects remain limited.
- ▶ Recent review of global MDR-TB trends, only 18 of 46 countries from the WHO African Region had nationwide drug resistance data, and only five had reported data since 2002 (3)



sample 1 sample 2 control sample 3 sample 4 sample 5




Con **Control free drug**
 Isoniacid
 Ri **Rifampicin**



INTERPRETATION OF RESULTS

Sample 1 Sample 2 Control Sample 3 Sample 4 Sample 5



▶ Sample 1 is - ve;

Negative

▶ Sample 2 is + ve;

Sensitive

▶ Sample 3 is +ve;

MDR

▶ Sample 4 is +ve;

INH
resistant


▶ Sample 5 is +ve;

RIF
resistant

Study Question

- ▶ With limited data existing on use of the (MODS) assay
 - Can MODS be used to diagnose MDR TB among Drug-Resistant Tuberculosis suspects in a high HIV prevalence setting?

Objectives

- ▶ To estimate the diagnostic accuracy of the MODS assay for *M. tuberculosis* detection against MGIT and solid LJ among MDR-TB suspects in a high HIV-prevalence region.
 - ▶ To assess accuracy of MODS DST against a reference standard absolute concentration method.
 - ▶ To determine sensitivity and specificity of the MODS Assay for detection of resistance to isoniazid, rifampicin and (MDR-TB)
 - ▶ To determine median turn around time for MDR TB detection .
- 

Study Methodology

Study Design

- An operational research study carried out in the Biomedical Research and Training Institute (BRTI) TB Laboratory at the National Microbiology Reference Laboratory in Harare.



Study Methodology

▶ **Study population**

- (DR TB) suspect patients undergoing routine work-up and from participants of ongoing clinical studies.
 - six previously cultured MDR isolates included for assessment of DST accuracy.

➤ ***Inclusion Criteria***

- DR TB suspects defined by :
 - ✓ history of prior treatment (> 1 month, classified according to WHO criteria (1))
 - ✓ contact to an individual with known or suspected drug-resistant TB.
- In addition

▶ ***Exclusion Criteria***

- New TB diagnosis cases
- Follow up of MDR TB treatment

Sample flow chart





Figure1. Study Flow Diagram




† One sample was reference standard negative and MODS contaminated, and thus excluded from specificity calculation.

Table 2. Comparison of the Microscopic-observation Drug-Susceptibility (MODS) Assay with Reference Standard Culture for Detection of *M. tuberculosis*

MODS Assay	Reference Standard Culture
No. of samples positive for <i>M. tuberculosis</i> by reference standard method (%)	
All directly inoculated samples (n=97)	
Sensitivity, % (95% CI)	86 (70-95)
Specificity, % (95% CI)	93 (84-98)
Positive predictive value, % (95% CI)	88 (73-97)
Negative predictive value, % (95% CI)	92 (82-97)
HIV-positive (n=39)*	
Sensitivity, % (95% CI)	85 (55-98)
Specificity, % (95% CI)	92 (73-99)
Positive predictive value, % (95% CI)	85 (55-98)
Negative predictive value, % (95% CI)	92 (73-99)
HIV-negative (n=20)*	
Sensitivity, % (95% CI)	86 (42-100)
Specificity, % (95% CI)	100 (74-100)
Positive predictive value, % (95% CI)	100 (54-100)
Negative predictive value, % (95% CI)	93 (64-100)


*Among persons with known HIV status (n=59/97 (61%)).

Figure 2. Kaplan-Meier Plot of Time to *M. tuberculosis* Detection



The median time to culture positivity was significantly shorter for MODS than manual MGIT (MODS 7 days [IQR 7–15 days] vs. MGIT 12 days [IQR 6–16 days]).

Results (cont)



- ▶ Median TAT for MDR TB diagnosis for MODS was (7 d {IQR 6-16 days}) was significantly shorter than for the absolute conc. method (70 d {IQR 49-96})

Table 3. Drug-Susceptibility Test Results from the MODS Assay

	Isoniazid	Rifampin	Isoniazid + Rifampin (multidrug resistance)
No. of samples*	31	31	31
No. resistant (prevalence)†	15/25 (60%)	17/25 (68%)	15/25 (60%)
Sensitivity, % (95% CI)	96 (59-96)	96 (79-100)	96 (59-96)
Specificity, % (95% CI)	89 (52-100)	88 (47-100)	89 (52-100)
Positive predictive value, % (95% CI)	96 (77-100)	96 (79-100)	96 (77-100)
Negative predictive value, % (95% CI)	89 (52-100)	88 (47-100)	89 (52-100)

*Analysis limited to samples with positive microscopic-observation drug-susceptibility and reference standard culture.

†Among directly inoculated patient specimens.

sensitivity and specificity of the MODS assay for detection of resistance to isoniazid, rifampin, and MDR-TB on concurrent DST results,

Conclusion

- ▶ In a high HIV-prevalence setting, MODS detected *M. tuberculosis* and *M. tuberculosis* drug resistance with high sensitivity and more rapid time to positivity compared with standard culture and DST methods.
- ▶ No detectable differences in diagnostic accuracy were noted for HIV-infected individuals
- ▶ Although debate continues with regards to the best scale-up option for DST in resource limited settings, (4) the short turnaround time, high accuracy, low cost, relative ease of operational implementation, and ability to discern both isoniazid and rifampicin resistance should make MODS a strong consideration.

4 Moore DA, Shah NS. Alternative methods of diagnosing drug resistance--what can they do for me? The journal of infectious diseases. 2011 Nov 15;204 Suppl 4:S1110-9.


Conclusion (cont)

- ▶ Studies focused on patient-important outcomes, along with population-based sampling methods to generate valid estimates of the prevalence and incidence of MDR-TB in modern-era Zimbabwe, are urgently needed.
- ▶ Prompt treatment of patients with MDR-TB and screening of their contacts will be essential to prevent further spread of drug-resistant *M. tuberculosis*;

Acknowledgements

▶ **Co Authors**

Professor Peter Mason, Prof John Z. Metcalfe, Reggie Mutetwa, Lucy Mupfumi, Jesca Mhaka, Salome Makumbirofa.

- ▶ NMRL where the BRTI TB Lab is housed.
 - ▶ Harare City Health Department and treating clinicians and staff at Wilkins Hospital MDR-TB Clinic.
 - ▶ Laboratorio de Investigación en Enfermedades Infecciosas de la UPCH and Dr. Robert H. Gilman
- 



Thank you.